Piramal Imaging Highlights New Data for Florbetaben and Other Investigational Radiopharmaceuticals at SNMMI 2013

USA - English

• USA - English
• USA - español
• USA - Français

BERLIN, BOSTON and MUMBAI, India, June 6, 2013 /PRNewswire/ -- Piramal Imaging announced today that results from four studies evaluating the Company's PET amyloid imaging agent (florbetaben F18^*) will be presented at the 2013 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI 2013) taking place in Vancouver from June 8-12.

Additionally, Andrew Stephens, Vice President of Clinical Research and Development at Piramal Imaging will present an update and highlights on florbetaben PET imaging in clinical trials as part of SNMMI's Emerging Technologies Session on Neurodegenerative Imaging on Monday, June 10 at 12:00 p.m. in the West Building, room 306. Dr. Stephens' presentation will highlight the clinical experience with florbetaben which is based on more than 900 applications at imaging centers across the U.S., Europe, Japan and Australia. The florbetaben development program comprises six phase 1 studies, two global, multicenter phase 2 studies, an MCI study with two year follow-up, and a global, multicenter histopathology phase 3 study.

"This year's annual meeting marks an important time as we look to commercialize florbetaben," said Dr. Stephens. "Our clinical presentations at SNMMI further highlight Piramal Imaging's commitment to advance the early detection of Alzheimer's disease as well as our research to develop investigational radiopharmaceuticals to address major clinical needs in oncology, specifically prostate cancer."

Florbetaben is currently being reviewed by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for use in the visual detection of beta-amyloid in the brains of adults with cognitive impairment who are being evaluated for Alzheimer's disease (AD) and other causes of cognitive decline. Presentations highlighting Florbetaben and the Company's pipeline compounds include:

Florbetaben F18

-- Close to clinical routine phase 2 trial on florbetaben PET imaging of β-amyloid (Aβ) in Alzheimer's disease (AD) [Abstract #299]
Scientific Paper Session (Oral) Neuroscience: Tau and Amyloid Imaging
Tuesday, June 11, 8:00 - 8:12 a.m., West Building, Room 215-216

-- Reliability, reproducibility and efficacy of the 18F florbetaben β-amyloid PET scan visual assessment method as trained via a computer-based instructional tool  [Abstract #300]
Scientific Paper Session (Oral) Neuroscience: Tau and Amyloid Imaging
Tuesday, June 11,  8:12 – 8:24 a.m., West Building, Room 215-216

-- Age-dependent 18-F florbetaben brain PET uptake in adults with Down's syndrome [Abstract #468]
Scientific Paper Session (Oral) Prediction of Cognitive Dysfunction and Multimodal Imaging
Tuesday, June 11, 2:57 – 3:09 p.m., West Building, Room 215-216

-- Effects of a partial volume correction on [18F]florbetaben PET for the assessment of longitudinal β-amyloid load in APP-Swe mice  [Abstract #1754]
Scientific Poster Session Poster Section: MTA II: Basic Science (Neurosciences) Posters
Tuesday, June 11, 2:45 p.m., West Building, Exhibit Hall A

FEMPA F18

-- Increased in vivo binding of [18F]FEMPA to the 18-kDa translocator protein in Alzheimer`s disease [Abstract # 137]
Scientific Paper Session (Oral) INTEGRATED Session: Inflammation Imaging and Neurological Disease
Monday, June 10, 10:24-10:36 a.m. West Building, Room 215-216

FSPG F18

-- Pilot clinical trial of (4S)-4-(3-[18F]fluoropropyl)-L-glutamate PET in patients with prostate cancer [Abstract # 285]
Scientific Paper Session (Oral) Prostate/GU1
Tuesday, June 11, 8:00 – 8:12 a.m., West Building, Room 221-222

-- Characterization of physiological 18F-FSPG uptake in healthy volunteers and comparison to 18F-FDG [Abstract # 63]
Scientific Paper Session (Oral) Nuclear Oncology Council YIA Symposium
Sunday, June 9, 4:30-4:42 p.m., West Building, Room 224  

PMPA (BAY 1075553)

-- PMPA (BAY 1075553) PET/CT in the detection of primary prostate cancer - Phase I study [Abstract # 1590]
Scientific Poster Session Poster Section: MTA I: Prostate/GU Posters Session Info: Meet the Author Poster Session I
Monday, June 10, 2:30 p.m., West Building, Exhibit Hall A

To learn more about Piramal Imaging, visit IBA's booth #610 at SNMMI.

NOTE TO EDITORS: All data is embargoed until the date/time of presentation.

About Piramal Imaging SA

Piramal Imaging SA, a division of Piramal Enterprises, Ltd., was formed in 2012 with the acquisition of the molecular imaging research and development portfolio of Bayer Pharma AG. By developing novel PET tracers for molecular imaging, Piramal Imaging is focusing on a key field of modern medicine. Piramal Imaging strives to be a leader in the Molecular Imaging field by developing innovative products that improve early detection and characterization of chronic and life threatening diseases leading to better therapeutic outcomes and improved quality of life. For more information please go to http://imaging.piramalenterprises.com.

About Piramal Enterprises Ltd.

Piramal Enterprises is one of India's largest diversified companies, with a presence in pharmaceutical, financial services and information management sectors. Piramal Enterprises had consolidated revenues of over $650 million in FY2013. In the pharmaceutical space, PEL is one of leading custom manufacturing player globally, has presence in the global critical care segment with a portfolio of inhalation and injectable anesthetics and its OTC business is ranked no. 7 in India. PEL is also engaged in drug discovery & research and has strong pipeline of development products. In the financial services space, PEL has a real estate focused PE fund – Indiareit and a NBFC that is focused on lending to real estate and education sector. PEL's information management business, Decision Resources Group is a leading provider of information based services to the healthcare industry.

^*Florbetaben is an investigational PET amyloid imaging agent currently under review by the U.S. Food and Drug Administration and the European Medicines Agency.

For media inquiries, please contact:

SOURCE Piramal Imaging